Kaposi sarcoma of unspecified primary site ICD11 code: 2C27.Z
Complementary For intravenous use only
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
EML status history
Adolescents and adults
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for vinblastine on the complementary list of the EML for use in treatment protocols for Kaposi sarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Kaposi sarcoma is attached.